Head & Neck Cancers | Specialty

The head & neck cancers condition center is a comprehensive resource for clinical news and expert insights on head & neck cancers. Read more at OncLive.

Dr Adkins on the FDA Approval of Pembrolizumab for Neoadjuvant/Adjuvant Treatment in Resectable, Locally Advanced HNSCC

June 12th 2025

Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.

FDA Approves Perioperative Pembrolizumab for Resectable, Locally Advanced HNSCC

June 12th 2025

The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.

Postoperative Nivolumab Plus SOC Extends DFS in Resected, High-Risk Head and Neck Cancer

June 1st 2025

Patients with locally advanced, high-risk head and neck cancer showed significantly improved DFS with adjuvant nivolumab plus cisplatin and radiotherapy.

CHMP Recommends EU Approval of Frontline Tislelizumab/Chemo for Metastatic Nasopharyngeal Carcinoma

May 27th 2025

The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.

FDA Approval of Penpulimab Expands Treatment Options in Recurrent/Metastatic Non-Keratinizing NPC

May 15th 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

Frontline Eftilagimod Alpha/Pembrolizumab Yields Favorable OS in PD-L1–Negative HNSCC

May 5th 2025

Treatment with eftilagimod alpha plus pembrolizumab produced a median OS of 17.6 months in the first line for patients with PD-L1–negative HNSCC.

Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer

April 29th 2025

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC

April 27th 2025

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

FDA Approves Penpulimab for Non-Keratinizing Nasopharyngeal Carcinoma

April 24th 2025

The FDA has approved penpulimab for select patients with non-keratinizing nasopharyngeal carcinoma.

Deintensification of Treatment Modalities Is Crucial to Consider in Head and Neck Cancer

April 24th 2025

Zafar Sayed, MD, explains advances in surgical head and neck cancer approaches, including the use of transoral robotic surgery.

Cultural Competency and Respect Are Crucial for Addressing Disparities in Cancer Care

April 23rd 2025

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Subtype-Specific Considerations, Surgical Innovation, and Functional Preservation Are Central to HNSCC Management

April 18th 2025

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Q2 2025: 7 FDA Decisions to Watch in the Realm of Oncology

April 5th 2025

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Penpulimab Gains NMPA Approval for First-Line Treatment of Recurrent or Metastatic NPC

March 18th 2025

Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

March 14th 2025

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

AVA6000 Generates Early Efficacy, Is Safe in Advanced Salivary Gland Cancers

March 14th 2025

AVA6000 showed early efficacy and safety signals in previously treated, locally advanced or metastatic salivary gland cancers.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

Versamune HPV–Based Immunotherapy Combo Demonstrates Benefit in Advanced HPV-Associated Cancers

March 6th 2025

Versamune HPV plus PDS01ADC and bintrafusp alfa demonstrated clinical benefit in locally advanced or metastatic HPV-associated cancers.

The OncFive: Top Oncology Articles for the Week of 2/23

March 1st 2025

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.